Promega Kit Enables European Forensic Labs to Solve Challenging Cold Cases
Forensic laboratories in Europe now have a new DNA analysis kit to efficiently process challenging casework samples. The PowerPlex® 18E System, launched by Promega Corporation, uses eight-color short tandem repeat (STR) analysis chemistry to extract more usable information from challenging samples. The kit includes all DNA markers recommended by the European Network of Forensic Science Institutes (ENFSI).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240506250730/en/
“Different regions have their own legal requirements and databases, as well as distinct genetic variations in their populations,” says Anupama Gopalakrishnan, Senior Product Manager at Promega Corporation. “This kit meets European forensic laboratories’ unique needs while also giving them more information from challenging DNA samples compared to earlier chemistries.”
Next-generation eight-color STR kits
STR analysis is the most widely used tool in human identification efforts. Most kits rely on five or six colors of dyes to mark regions of DNA that can help identify a match. Promega introduced the first commercially available eight-color STR multiplex chemistry in 2023 and expands on that product family with the PowerPlex® 18E System.
PowerPlex® 18E System features include:
- 18 loci aligned with recommendations from ENFSI: The kit includes the SE33 locus, which has been shown to be particularly informative for analyzing DNA samples from European populations. At 170-324 base pairs, the size of the SE33 locus is the smallest of all commercially available multiplexes.
- All loci amplicons less than 325 base pairs in length: Shorter amplicons are less likely to disappear during STR analysis, helping labs avoid data loss when working with degraded or limited samples.
- Quality indicators for efficient troubleshooting: If an experiment fails to produce a usable profile, the quality indicators provide a quick visual cue for what might have gone wrong, such as inhibition, degradation or lack of DNA in the sample.
The PowerPlex® 18E System and other eight-color kits are intended to be used with the Spectrum CE System and the Spectrum Compact CE System, capillary electrophoresis instruments offered by Promega that support eight-color fragment analysis. Promega has been developing and manufacturing products for DNA-based human identification for more than 30 years.
Learn more about the PowerPlex® 18E System at www.promega.com/Introducing18E
About Promega Corporation
Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s portfolio of over 4,000 products supports a range of life science work across areas such as cell biology; DNA, RNA and protein analysis; drug development; human identification and molecular diagnostics. These tools and technologies have grown in their application over the last 45 years and are used today by scientists and technicians in labs for academic and government research, forensics, pharmaceuticals, clinical diagnostics and agricultural and environmental testing. Promega is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors. Learn more at www.promega.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240506250730/en/
Contact information
Penny Patterson
VP, Corporate Affairs
Promega Corporation
Phone: (608) 274-4330
E-mail: penny.patterson@promega.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB OneSubsea awarded subsea boosting contract by Petrobras for the Búzios field, offshore Brazil12.12.2024 14:22:00 CET | Press Release
Global energy technology company SLB (NYSE: SLB) today announced a contract award by Petrobras, following a competitive tender, to its OneSubsea™ joint venture for two subsea raw seawater injection (RWI) systems to increase recovery from the prolific Búzios field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241212795762/en/ Under the contract, SLB OneSubsea will provide two complete subsea RWI systems to support Petrobras’ FPSOs P-74 and P-75, and they will each consist of a subsea seawater injection pump, umbilical system and topside variable speed drive. (Photo: Business Wire) The subsea RWI systems will help to increase the production of floating production storage and offloading (FPSO) vessels, which are currently bottlenecked in their water injection capacities. Once operational, the RWI systems will reduce greenhouse gas (GHG) emissions per barrel of oil as they are a more efficient means of reservoir pressurization
EnerSys Wins Prestigious German ESG Transparency Award12.12.2024 14:15:00 CET | Press Release
EnerSys(NYSE: ENS), the global leader in stored energy solutions for industrial applications, is proud to announce it has been honored with the German ESG Transparency Award. This distinguished accolade recognizes organizations that demonstrate exemplary transparency and accountability in their environmental, social, and governance (ESG) initiatives. The ESG Transparency Award, presented annually in Germany, highlights the importance of clear and comprehensive ESG reporting as a cornerstone of corporate responsibility. This recognition underscores EnerSys’ steadfast commitment to sustainable practices and its leadership in advancing ESG standards within the industrial energy sector. “Receiving the ESG Transparency Award is a tremendous honor and a testament to EnerSys' dedication to transparency and continuous improvement in our global sustainability journey. At EnerSys, we believe in ‘Powering the Future, Everywhere for Everyone,’ and this recognition underscores our commitment to con
Parse Biosciences Launches Evercode Mouse BCR to Support Antibody Engineering and Development for Drug Discovery Applications12.12.2024 14:15:00 CET | Press Release
Parse Biosciences, a leader in scalable single cell sequencing solutions, today announced the expansion of its Evercode BCR™ product line to enable applications in mice. The new kits enable researchers to profile the mouse BCR repertoire alongside whole transcriptome data for millions of cells in a single experiment, offering unmatched scale and efficiency for antibody discovery. The Evercode BCR platform is designed to streamline workflows for antibody research, allowing scientists to identify individual antibody-producing cells and their clonally-related groups that generate specific antibodies of interest. Unique features, such as sample fixation capabilities, allow researchers to preserve cells and samples from mice for up to six months, thereby reducing the need to harvest additional mice and maximizing the yield per discovery campaign. Further, the technology eliminates the requirement for costly equipment, making advanced single cell analysis accessible with standard laboratory
1NCE Trains Software Innovators on Simplifying IoT Solutions12.12.2024 14:15:00 CET | Press Release
1NCE, one of the fastest-growing companies in the Internet of Things (IoT), announces the launch of its Certified Integrators Program (CIP). The program empowers external software developers to integrate seamlessly with 1NCE’s IoT platform, simplifying the development of connected solutions and enhancing customer success. The program marks a new step for 1NCE’s Partner Initiative, which counts more than 80 companies supporting 1NCE and its 23,000 customers managing 30 million endpoints worldwide. By offering hands-on training and certification, 1NCE equips integrators with tools to deliver streamlined, cost-effective IoT implementations for businesses across industries. A key aspect of 1NCE's strategy is its dedication to providing open access, enabling top software developers to collaboratively build connected products on the 1NCE platform. The CIP starts with a comprehensive education program for partners to become certified experts in 1NCE’s IoT platform, then continues with teachin
Tanner Pharma Expands Global Access to Botensilimab and Balstilimab Through Partnership With Agenus12.12.2024 14:00:00 CET | Press Release
Tanner Pharma, a global provider of specialty medicine access solutions, today announced a collaboration with Agenus, a leading immuno-oncology company, to provide expanded access to botensilimab (BOT) and balstilimab (BAL). Through a Named Patient Program (NPP), this initiative offers patients with microsatellite stable colorectal cancer (MSS CRC) and other advanced solid tumors the opportunity to access BOT/BAL based on supporting clinical evidence and medical need. Tanner Pharma will manage access to BOT/BAL for patients in geographies that allow named patient access to investigational medicines. The NPP ensures that patients, in consultation with their physicians, can access BOT/BAL even before regulatory approval, adhering to all ethical and compliance standards. BOT and BAL are investigational immunotherapies designed to target challenging cancers, including MSS CRC and other tumors historically resistant to immune-based treatments. Clinical outcomes have demonstrated complete pa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom